Emergent Biosolutions (EBS) Stock Statistics & Valuation Metrics

Emergent Biosolutions has a market cap or net worth of $586.65M. The enterprise value is $920.13M.

Emergent Biosolutions has 52,519,962 shares outstanding. The number of shares has decreased by -2.65% in one year.

Emergent Biosolutions’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -11.79%.

The current PE Ratio of Emergent Biosolutions is 8.6. Emergent Biosolutions’s PEG ratio is 0.04.

In the last 12 months, Emergent Biosolutions had revenue of 1.04B and earned -190.60M in profits. Earnings per share was -3.60.

In the last 12 months, operating cash flow was 13.00M and capital expenditures -11.60M, giving a free cash flow of 1.40M billion.

Emergent Biosolutions pays an annual dividend of ―, resulting in a dividend yield of ―

Emergent Biosolutions upcoming earnings date is Mar 10, 2026, TBA (Confirmed).

Emergent Biosolutions as a current ratio of 3.69, with Debt / Equity ratio of 113.84%

In the past 12 months, Emergent Biosolutions has paid 47.70M in taxes.

Emergent Biosolutions EV to EBITDA ratio is 20.29, with an EV/FCF ratio of 30.26.

Emergent Biosolutions has $245.50M in cash and marketable securities with $663.10M in debt, giving a net cash position of -$417.60M billion.

Gross margin is 57.80%, with operating margin of -10.42%, and net profit margin of -18.26%.

The average price target for Emergent Biosolutions is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy